By continuing browsing this website, you accept the use of cookies to help us improve your user experience. Read more.

A probiotic yeast scientifically recognized at Lesaffre Human Care

Lesaffre Human Care is launching the first known probiotic yeast to specifically target Irritable Bowel Syndrome (IBS) symptoms. With a clinically proven effect in relieving intestinal problems in individuals with IBS, Lesaffre Human Care’s patented strain of Saccharomyces cerevisiae, CNCM I-3856, is a real breakthrough.

A probiotic yeast known on the market under the commercial name of Lynside® Pro GI+.

The results of a clinical study published in February in the journal “digestive and liver disease” have confirmed the benefits of Lesaffre Human Care’s patented probiotic yeast saccharomyces cerevisiae cncm i-3856.

The study of 200 volunteers* overseen by Professor Pierre Desreumaux, international specialist in inflammatory bowel diseases at the University of Lille, demonstrates a significant impact on relieving abdominal pain and/or discomfort in subjects suffering from Irritable Bowel Syndrome (IBS). “Lynside® Pro GI+ is the first known probiotic yeast to precisely target IBS and it was essential for us to obtain scientific proof of its efficacy”, stresses Amélie Cayzeele-Decherf, in charge of the clinical studies at LHC.

A probiotic yeast with no adverse effects

Another major advantage: this probiotic yeast is well tolerated and the analgesic effect observed is not outweighed by adverse effects. Lynside® Pro GI+ is therefore a natural and well tolerated solution to intestinal problem over the long term, effectively relieving the symptoms with no adverse effect or dependency.

IBS considerably affects the quality of life of patients and is considered to be one of the most common functional gastrointestinal disorders in the world, affecting up to 20% of adults in some regions and representing one of the main causes of absence from work.

* 200 volunteers were administered either 500 mg of Saccharomyces cerevisiae CNCM I-3856, or a placebo, for 4 weeks.

Télécharger le communiqué